ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / HALO / earnings
NBIX (73) EXEL (91) TECH (72) KYMR (51) ⌘ Pro Terminal →

Halozyme Therapeutics Inc. (HALO) Next Earnings Date & Expected ±5.4% Move

$130.91 -0.21% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $131.17

Halozyme Therapeutics Inc. (HALO) earns a Roarable Rating of B (Buy) with 75/100 RQD Confidence. High-quality cash engine (84% profit margin, 18% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 75/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.4% avg 90D alpha vs SPY • 69.7% hit rate) →
ROARABLE B • BUY Cap $14.86B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on HALO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is HALO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Halozyme Therapeutics Inc. (NASDAQ: HALO) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 75/100 at a spot price of $130.91 (-0.21% 1D, market cap $14.86B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, HALO ranks #32 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does HALO compare to NBIX and EXEL in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), HALO carries a Roarable B (75/100 RQD), trailing P/E of 47.0x, gross margin of 83.6%, and ROIC of 18.0%. By comparison, NBIX (Neurocrine Biosciences Inc.) holds a B grade (73/100 RQD, P/E 31.1x, ROIC 15.7%, cap $14.85B) and EXEL (Exelixis Inc.) posts a A grade (91/100 RQD, P/E 21.0x, ROIC 35.1%, cap $16.93B). Among the 5-stock peer group, EXEL leads on earnings multiple (21.0x) while EXEL leads on capital efficiency (35.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for HALO?
▼

Per HALO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001159036), Halozyme Therapeutics Inc. generated $1.40B in revenue (+37.6% YoY), $316.9M in net income, and $644.6M in free cash flow against $2.53B in total assets and $2.14B in total debt. Key quantitative strengths: Strong cash generator (84% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 47x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $131.17 (+0.20%)🧬 Cannibal Buyback (-1.52% YoY Shares)⚙️ Cash Engine: 18/20 (A) • 46.2% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 75/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.4% avg 90D alpha vs SPY • 69.7% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B
025507510075
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw A- · Rk C
Cash (18)Whales (18)SEC (15)Macro (11)CEO (13)
Each axis scored 0–20
12M PRICE TARGET CONE+7.6% Base Target
$166 Bull$141 Base$107 Bear
📬 FREE HALO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HALO)Realized 20D OHLCV Swing Band: ±5.4%
Deterministic 5-Pillar Attribution (75/100 Composite)
🔍 WHY HALO SCORES 75/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+18/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 46.2% FCF Margin ($644.6M FCF) & 83.6% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+18/20 pts (24% of score)

20D Institutional Volume Accumulation (±5.4% realized swing band)

▼ #1 Drag / Risk Factor: Macro Regime Fit11/20 pts (-9 pt drag)

Macro rate sensitivity & RSI-14 (77.8) create a -9 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
67
Grade B-$116.82+6.9% Next Q
Q2 (-2Q)
70
Grade B$124.83+4.2% Next Q
Q3 (-1Q)
72
Grade B$130.03+0.7% Next Q
Current
75
Grade B$130.91+7.4% Hist 90D α
Trajectory: B- (67) → B (75)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the HALO Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 75/100 (B) score, HALO faces multiple-compression risk if 47.0x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 47x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.52% YoY Shares) — any gross margin slip below 81.1% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($115.05) or 200D SMA ($84.27) invalidates the momentum regime and cuts Target Base ($140.92) toward Bear Floor ($107.35).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $HALO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “HALO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 75%NO 25%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±5.4% Swing Band

±$7.07 Expected Swing
$123.84 (-5.4%)Spot $130.91$137.98 (+5.4%)
MODEL EARNINGS SETUP GAUGE

HALO Quantitative Pre-Earnings Setup: 75/100

Trailing EPS: $2.79 • YoY Revenue Growth: 37.6%

Model Bullish Setup (75/100)Model Risk Weight (25/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$1.40B$316.9M$644.6M83.6%
FY 20242024-12-31$1.02B$444.1M$468.4M84.3%
FY 20232023-12-31$829.3M$281.6M$351.3M83.6%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating HALO & AI Leaders Without Chasing Tops

  • ✓Institutional whale strikes & implied earnings move audit on HALO
  • ✓How disciplined traders manage risk using pre-published trigger & invalidation levels
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
HALO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +102.74%⚡ TESTING RESISTANCE
2026-11-03O $131.2H $131.2L $130.9C $130.9VOL 1.40M
RES: $135.8SUP: $96.47SMA50: $115.1SMA200: $84.27
$139.0$118.4$97.85$77.29$56.73RES $135.8SUP $96.47$130.92026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HALO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HALO Butterfly Map → + Track HALO →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
34.7%/yr Implied 5Y Growth

vs. +37.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on HALO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HALO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for HALO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HALO)

Health Care Rank #32 of 1016 ⚔️ NBIX vs HALO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HALO vs. NBIX, EXEL, TECH, KYMR)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Halozyme Therapeutics Inc. (HALO) ranks #32 by composite RQD confidence (75/100, grade B) and #80 by equity capitalization ($14.86B). Within this direct 5-issuer industry benchmark cohort, EXEL leads on earnings valuation at 21.0x trailing P/E, while EXEL leads on capital efficiency and profitability with 35.1% ROIC and 96.0% gross margin. EXEL currently holds the highest overall quantitative score in the immediate peer group at 91/100 (A) compared with HALO at 75/100 (B).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
HALO ACTIVE
Halozyme Therapeutics Inc.
B 75/100 47.0x 83.6% 18.0% -0.21% $14.86B Benchmark Subject
NBIX
Neurocrine Biosciences Inc.
B 73/100 31.1x 96.0% 15.7% -0.19% $14.85B /nbix-vs-halo →
EXEL
Exelixis Inc.
A 91/100 21.0x 96.0% 35.1% +4.82% $16.93B /exel-vs-halo →
TECH
Bio-Techne Corp
B 72/100 155.3x 64.8% 3.4% -0.07% $11.39B /tech-vs-halo →
KYMR
Kymera Therapeutics Inc.
D 51/100 32.7x — -21.4% +3.29% $10.81B /kymr-vs-halo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001159036

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Halozyme Therapeutics Inc. (HALO) reported GAAP revenue of $1.40B (+37.6% vs. FY2024 revenue of $1.02B , and +68.4% cumulative change since FY2023) , GAAP net income of $316.9M, operating cash flow of $651.6M, and free cash flow of $644.6M (+37.6% YoY). On the balance sheet, HALO closed FY2025 with $2.53B in total assets against $2.14B in total debt (Altman Z-Score: 5.11, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $1.40B $316.9M $651.6M $644.6M $2.53B $2.14B
FY2024 (FY) 2024-12-31 $1.02B $444.1M $479.1M $468.4M $2.06B $1.51B
FY2023 (FY) 2023-12-31 $829.3M $281.6M $388.6M $351.3M $8.19B $1.92B

3. HALO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HALO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Halozyme Therapeutics Inc. (NASDAQ: HALO) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 75/100 at a spot price of $130.91 (-0.21% 1D, market cap $14.86B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, HALO ranks #32 in composite RQD confidence.

How does HALO compare to NBIX and EXEL in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), HALO carries a Roarable B (75/100 RQD), trailing P/E of 47.0x, gross margin of 83.6%, and ROIC of 18.0%. By comparison, NBIX (Neurocrine Biosciences Inc.) holds a B grade (73/100 RQD, P/E 31.1x, ROIC 15.7%, cap $14.85B) and EXEL (Exelixis Inc.) posts a A grade (91/100 RQD, P/E 21.0x, ROIC 35.1%, cap $16.93B). Among the 5-stock peer group, EXEL leads on earnings multiple (21.0x) while EXEL leads on capital efficiency (35.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for HALO?

Per HALO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001159036), Halozyme Therapeutics Inc. generated $1.40B in revenue (+37.6% YoY), $316.9M in net income, and $644.6M in free cash flow against $2.53B in total assets and $2.14B in total debt. Key quantitative strengths: Strong cash generator (84% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 47x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is HALO trading relative to its 50-day, 200-day, and 52-week technical levels?

HALO last traded at $130.91 (-0.21% on volume of 1,402,663 shares), positioning the stock +13.79% above its 50-day simple moving average ($115.05) and +55.35% above its 200-day simple moving average ($84.27). Across its 52-week range of $61.23 to $134.00, HALO sits at the 95.8% percentile with a 14-day RSI of 77.8 (OVERBOUGHT (>70)) and an implied next-earnings move of ±5.4% ($123.84 to $137.98).

Direct Sub-Reports: HALO RQD Cockpit HALO 12M Forecast HALO Earnings & Move HALO Dividends & DRIP HALO Insiders & 13F HALO Whale Options HALO Profit Sankey HALO News & Why
ROARABLE RATING BRIEF • RQD 75/100 (B) ✓ STAGE-C NUMBER FIREWALL VERIFIED

HALO — Halozyme Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:14:44Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, HALO scores 75 out of 100, a letter grade of B, labeled "Roarable Buy — Good Risk/Reward." The five pillars are:

  • Fundamental Cash Engine: 18 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of 18% and an FCF yield of 4.33%. For a prospective investor, this is the strongest support for the rating: the business converts capital into returns at a high rate, though the 4.33% FCF yield indicates the market is pricing the stock at a rich multiple of current cash generation.
  • Whale 13F Flow: 18 / 20. Per the Roarable RQD rating, this pillar captures institutional accumulation and options positioning.
  • Insider Conviction: 13 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. This is a moderate reading, suggesting insider signals are supportive but not decisively so.
  • Macro Regime Fit: 11 / 20. Per the Roarable RQD rating, this pillar reflects a beta of 0.88 and sector sensitivity. A beta below 1 implies below-market sensitivity to broad moves, a defensive feature, yet the pillar's below-midpoint score signals weaker fit with the current macro backdrop.
  • Forensic Balance Sheet: 15 / 20. Per the Roarable RQD rating, this pillar reflects an Altman Z of 5.11, a Piotroski F of 7/9, and Debt/Equity of 8.5. The Z and F readings are favorable; the leverage figure is the principal caution.

Taken together, the rating points to quality operations and institutional support offset by valuation (P/E TTM of 47) and macro-fit weakness. Valuation tradeoffs are central: the stock trades at a premium multiple, so upside depends on sustained earnings growth.

Recent Catalysts & News Wire Analysis

Per the recent news feed, six items reference HALO:

  • CATALYST (GREEN): An earnings-expectations preview ("Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?") and a report on strong earnings growth sending shares higher.
  • RISK WATCH (RED): A Trefis piece asking what investors missed before a run, flagged as a risk item.
  • MARKET WIRE (YELLOW): Items from Yahoo! Finance Canada, ChartMill (a value/profitability note), and Investing.com (a note on the stock climbing).

Per the Butterfly supply-chain graph, the supply chain is listed as "NONE," with no butterfly links and no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly supply-chain graph, the supply chain is "NONE," with no butterfly links and no proprietary signals. Upstream dependencies, downstream customers, and sector correlations are therefore — A prospective investor should note that second-order effects cannot be mapped from this dataset; the beta of 0.88 is the only provided measure of market co-movement.

Analyst View & Smart Money Ownership

— The analyst data and holders sections are both empty ("NONE"), so no consensus rating, price targets, SEC Form 4 insider trades, 13F whale holdings, or Congressional trades are provided. The Roarable RQD pillars reference insider and institutional flow scores (13/20 and 18/20), but the underlying transactions are not itemized.

Open Questions

  • What drove the decline in net income from $444.1M (FY 2024) to $316.9M (FY 2025) despite revenue growth?
  • What is the composition of the $2.14B debt, and what is the debt maturity and interest-cost profile?
  • What were the actual earnings results and magnitudes behind the "strong earnings growth" headline?

4.

  • What are the specific 13F, options, and insider transactions underlying the RQD flow pillars?

HALO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Halozyme Therapeutics Inc. (HALO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to HALO Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

HALO Bull vs. Bear Conversation Board — What's Your Call at $130.91?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HALO 🐻 33% BEARISH CONVICTION
1. Pick Your Side on HALO:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH 🎯 Target: $154.79 (+18.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is HALO (B • RQD 75/100) a Buy at $131.18?

Welcome to the HALO (Halozyme Therapeutics Inc.) Roar Pit. Current RQD Composite is 75/100 (Roarable Buy — Good Risk/Reward) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to capital efficiency (18.0% ROIC), while bears focus on valuation multiple compression (47.0x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $99.70 (-24.0%)
Spot @ $131.18

Pump the brakes on HALO — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on HALO, but look at what you are paying: 47.0x trailing P/E with 83.6% gross margins. Unless Halozyme Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $166.60 (+27.0%)
Spot @ $131.18

HALO cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on HALO, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $131.18 (52-wk range $61.23 - $134.00), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%